MINNEAPOLIS, MN / ACCESSWIRE / January 11, 2024 / OneMedNet Corporation, ("OneMedNet" or the "Company") (NASDAQ:ONMD) the leading curator of regulatory-grade imaging Real World Data ("RWD"), today announced a partnership with Beacon Health System, Inc. to promote new patient care diagnostic and treatment solutions using OneMedNet's iRWD™. Life Science organizations of all types are taking advantage of existing real world data within several product development stages including conceptualization, development, validation, regulatory approval, and post-market surveillance.
"Life science organizations are continually faced with critical new product decisions at every step of the innovation process," said Aaron Green, OneMedNet President. "The key to flawless decision-making is to have flawless data upon which to base, and support, these decisions. We provide that data."
OneMedNet utilizes both the latest AI/ML technology as well as an industry-leading data curation team to ensure that the requested data precisely matches the required specification - no matter how detailed. This curation team has over 300 years of clinical experience and is clinically certified in every radiology modality.
The OneMedNet iRWD network consists of over 235 healthcare systems and providers who are well-recognized for their exceptional patient care. Importantly, these care leaders are also focused on fully supporting continued care advancements for the benefit of their patients, and others. This particular health system features 150+ care sites treating 1.5m patients per year.
About OneMedNet Corporation
Founded in 2009, OneMedNet provides innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers. Employing its proven OneMedNet iRWD™ solution, OneMedNet securely de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements. For more information, please visit www.onemednet.com.
Investor Contact
Shannon Devine
MZ Group North America
203-741-8811
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.88 |
Daily Change: | -0.10 -10.59 |
Daily Volume: | 108,834 |
Market Cap: | US$24.050M |
September 26, 2024 July 26, 2024 June 14, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB